Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
34
Participants
Timeline
Start Date
August 6, 2021
Primary Completion Date
October 22, 2021
Study Completion Date
November 21, 2021
Conditions
Healthy
Interventions
DRUG
BLU-5937
Single and multiple doses assessment
Trial Locations (1)
SE1 1YR
Richmond Pharmacology Ltd., London
All Listed Sponsors
lead
Bellus Health Inc. - a GSK company
INDUSTRY
NCT06179537 - Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter